Chen W, Ruan Z, Chen J, Yang D, Shao R, Lou H, Jiang B. On the population pharmacokinetics and the enterohepatic recirculation of hyzetimibe and its main metabolite in Chinese healthy subjects.
Br J Clin Pharmacol 2021;
88:3153-3161. [PMID:
34931372 DOI:
10.1111/bcp.15187]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 11/16/2021] [Accepted: 11/27/2021] [Indexed: 11/27/2022] Open
Abstract
BACKGROUNDS
Hyzetimibe (HS-25), a new drug approved for hypercholesterolemia, exhibits obvious enterohepatic recirculation (EHC) after oral administration. Up to now, little is known about the kinetics of HS-25. Therefore, we performed this population pharmacokinetic (PopPK) analysis aiming to describe the PK behavior of HS-25 and its main metabolite (M1), and to identify significant covariates contributing to the variability.
METHODS
The plasma concentration data used for modeling were obtained from an open-label, single-dose, randomized, two-period crossover bioequivalence study. PopPK modeling was performed with NONMEM 7.4.1 using nonlinear mixed effect modeling approach. Goodness of fit plots, bootstrap and visual predictive check were used for model internal validation. Data from another study was used for external validation.
RESULTS
Data from 16 male and 8 female subjects were used in the PopPK analysis. HS-25 and M1 concentrations in the modeling cohort were well described by a one-compartment model incorporating first-pass metabolism and a gallbladder compartment, accounting for the EHC process. The release kinetic of gall was mimicked by a first-order constant plus a switch on/off effect. Body weight was identified as a significant covariate effecting on the clearance and apparent distribution volume of HS-25, as well as kmg , the transfer rate from metabolite compartment to gallbladder compartment. Internal and external validation demonstrated an acceptable predictive ability of the final model.
CONCLUSIONS
We present the first PopPK model describing HS-25 and M1 concentrations simultaneously, with the EHC process considered. The modeling and simulation results could provide reference for the clinical use of HS-25.
Collapse